A Phase 3 interventional study of cabergoline and levodopa in Restless Legs Syndrome, sponsored by Pfizer. Completed at 50 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-10-29.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Restless Legs Syndrome with a site in Germany — 1 open to participants now, 2 under way, none of them phase 3. Restless Legs Syndrome · Germany.
Among the 28 studies in Restless Legs Syndrome with a site in Germany, this one is the 7th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2003, is one of 11 in phase 3, and was the 19th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →1 of the 28 studies in Restless Legs Syndrome with a site in Germany is open now. Recruiting first, the newest first:
Johannes Gutenberg University Mainz · Sites in Germany
Ages 18–120
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 361 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 316 across the 22 interventional studies, 1,096 across the 6 observational. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 9 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 2 studies filed under Restless Legs Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Restless Legs Syndrome with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with levodopa in the treatment of patients with RLS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: cabergoline
Drug: levodopa
Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events
Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
Change from baseline in the total score of the International RLS Study Group Rating Scale (IRLSSG-RS)
Time frame: Week 6
Time to dropout due to a necessary change in RLS therapy because of augmentation or loss of efficacy (e.g., dose increment of study drug, switch to another therapy, or start of a drug-free period)
RLS quality-of-life questionnaire
Time frame: Weeks 6 and 30
Clinical Global Impression
Time frame: Weeks 6 and 30
Patient Global Impression
Time frame: Weeks 6 and 30
Sleep questionnaire form A
Time frame: Weeks 6 and 30
IRLSSG-RS
Time frame: Week 30
Safety evaluation including adverse events, clinically relevant changes in laboratory data, physical exam findings, and abnormalities observed in electrocardiogram
Time frame: Weeks 2, 6, and 8 during Period 1 and every 4 weeks during Period 2
Rating of severity of RLS at night (RLS-6 scale)
Time frame: Weeks 6 and 30
Rating of severity of RLS before bedtime (RLS-6 scale)
Time frame: Weeks 6 and 30
Rating of severity of RLS at day when at rest and during activities, severity of daytime sleepiness (RLS-6 scales)
Time frame: Weeks 6 and 30
Global rating of quality of sleep (RLS-6 scale)
Time frame: Weeks 6 and 30
The record gives a start of Jan 2003 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cabergoline · Levodopa